A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

Ciara C. O’Sullivan,Karla V. Ballman,Linda Mackie McCall,Tyler Zemla,Anna Weiss,Melissa P. Mitchell,Victoria S. Blinder,Nadine Tung,William J. Irvin,Myounghee Lee,Matthew P. Goetz,William Fraser Symmans,Virginia F. Borges,Ian E. Krop,Ann H. Partridge,Lisa A. Carey

A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

2021

Ciara C. O’Sullivan
Karla V. Ballman
Linda Mackie McCall
Tyler Zemla
Anna Weiss
Melissa P. Mitchell
Victoria S. Blinder
Nadine Tung
William J. Irvin
Myounghee Lee
Matthew P. Goetz
William Fraser Symmans
Virginia F. Borges
Ian E. Krop
Ann H. Partridge
Lisa A. Carey

TPS595Background: Patients (pts) with HER2+ early breast cancer (EBC) and invasive residual disease (RD) after neoadjuvant therapy (NAT) have a higher risk of relapse than pts with a pathologic com...

Keywords:

Medicine
Internal medicine
Neoadjuvant therapy
Placebo
Oncology
Disease
in patient
relapse risk
Breast cancer
early breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations